Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Medicine and Dentistry

• Patient 100%
• DNA Repair 60%
• Gene 60%
• Analysis 60%
• Castration Resistant Prostate Cancer 50%
• Therapeutic Procedure 50%
• Adverse Event 30%
• Anemia 30%
• Inpatient 30%
• Prostate Cancer 20%
• Antineoplastic Activity 20%
• Androgen 20%
• Thrombocytopenia 20%
• Protein 10%
• Phenotype 10%
• Neoplasm 10%
• Diseases 10%
• Systemic Therapy 10%
• Follow up 10%
• Lethality 10%
• Histology 10%
• Sepsis 10%
• Somatics 10%
• Chemotherapeutic Agent 10%
• Development 10%
• Drug 10%
• Fatality 10%
• Response Evaluation Criteria in Solid Tumors 10%
• Neutropenia 10%
• Nausea 10%
• BRCA1 10%
• BRCA2 10%
• PARP Inhibitor 10%
• Tissues 10%
• Cells 10%
• Arm 10%
• Saliva 10%
• Oncology 10%
• Poly ADP Ribose Polymerase 10%
• Blood 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Castration Resistant Prostate Cancer 50%
• Niraparib 50%
• Adverse Event 30%
• Anemia 30%
• Prostate Cancer 20%
• Androgen 20%
• Taxane 20%
• Thrombocytopenia 20%
• Protein 10%
• Diseases 10%
• Neoplasm 10%
• Sepsis 10%
• Drug 10%
• Neutropenia 10%
• Nausea 10%
• Fatality 10%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 10%
• Urosepsis 10%
• Lethality 10%
• Death 10%

Biochemistry, Genetics and Molecular Biology

• Nested Gene 60%
• DNA Repair 60%
• Antineoplastic Activity 20%
• Poly ADP Ribose Polymerase 20%
• Thrombocytopenia 20%
• Phenotype 10%
• Cancer Staging 10%
• BRCA1 10%
• BRCA2 10%
• Germline 10%
• Development 10%
• Synthetic Lethality 10%
• Protein 10%
• Dose 10%